India's Syngene International on Monday said it has acquired its first biologics facility in the United States from Emergent ...

Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...

Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...

Biocon Biologics, one of India's leading biologic drug manufacturers, announced on Friday the results of a Phase-3 study on a ...

Biocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will ...

Syngene International acquires US manufacturing facility, expanding bioreactor capacity and global service capabilities for pharmaceutical innovation.

The rise in Biocon share price came after the company announced that its wholly-owned subsidiary, Biocon Pharma, has received ...

Introduction of a direct-to-patient delivery model for its weight-loss drug in the United States could potentially delay its ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), and Civica, Inc. (Civica), a not-for-profit generic drug and ...

Biocon Biologics partners with Civica to enhance access to Insulin Aspart in the US, no tech transfer involved.

Siddharth Mittal, MD and CEO of Biocon said the company will launch Liraglutide in Europe in FY26 along with its partner, ...

This collaboration is in addition to Biocon Biologics’ own insulin aspart drug product for the US, which is currently under ...